BD, 771894, RB670 Rat Anti-Human HER4 (ErbB4) P6-1

The P6-1 monoclonal antibody specifically recognizes the extracellular region of Human Epidermal Growth Factor Receptor 4 (HER4). HER4 is encoded by ERBB4 (erb-b2 receptor tyrosine kinase 4). HER4 (ErbB4) belongs to the epidermal growth factor receptor subfamily within the ERBB family of Receptor Tyrosine Kinases (RTK) that includes HER1 (EGFR), HER2 (ErbB2), and HER3 (ErbB3). HER4 (ErbB4) is an ~180 kDa type I transmembrane glycoprotein that contains an extracellular ligand-binding region, a transmembrane sequence, and a cytoplasmic tail with the active tyrosine kinase domain. This RTK functions in a variety of normal cellular processes including proliferation, differentiation, migration, survival, and apoptosis that are often dysregulated in cancer cells. HER4 (ErbB4) is prominently involved in regulating the development and maintenance of the heart, central nervous system, and mammary gland. Upon binding ligands, including neuregulins and EGF family members, HER4 (ErbB4) can homodimerize or heterodimerize with other family members and transmit intracellular signals involved in initiating and regulating cellular responses. High expression of ERBB4 occurs in brain, heart, kidney, and heart as well as skeletal muscle, bone marrow mesenchymal stem cells and breast tissue. Overexpression of and mutations in the ERBB4 gene have been associated with some leukemias, neuroblastomas, and carcinomas. The P6-1 antibody can reportedly suppress Neuregulin-1 (NRG-1)-dependent signaling and colony formation responses mediated through HER4 (ErbB4) expressed on human breast cancer cell lines.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
11. Tandem fluorochromes contain both an energy donor and an energy acceptor. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from the donor may be observed. Additionally, multi-laser cytometers may directly excite both the donor and acceptor fluorochromes. Therefore, we recommend for every tandem conjugate, a matched individual single-stain control be acquired for generating a compensation or spectral unmixing matrix.
12. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
13. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.